Advisory board

The Oxford Antibiotic Group has established a comprehensive network of advisors to support and optimize the company’s drug development strategies.

The Advisory Board is chaired by Prof. Dr. Mark Moloney, University of Oxford, and comprises a number of international experts in the field of compound development.

Prof. Dr. Mark Moloney

University of Oxford – Dept. of Chemistry

Mark is renowned academic at University of Oxford for more than 30 years. He is a synthetic organic chemist with broad spectrum of expertise, including natural products and materials chemistry. He has published more than 200 publications in high-ranking journals and has written four undergraduate textbooks. In his career Mark has extensive experience of interactions with industry, especially pharmaceuticals, is founding member of famous Antibiotic Discovery UK charity and is academic founder of Oxford Advanced Surfaces, a materials company in Oxford. He is one of the initiators of Oxford Antibiotic Group and leads the Oxford based research for the company.

Univ. Prof. Dr. Heinz Burgmann

Medical University Vienna, Clinical expert

Heinz holds a degree in human medicine. He is the head of the Department of Internal Medicine I, Div. of Infectious Diseases at the Medical University of Vienna and is Austria’s chief expert for resistant microbes and clinical infections. With his research activities and his involvement in many clinical studies, he has gained a comprehensive knowledge in pre-clinical and clinical development, with more than 100 publications in the field of anti-infective substances.

Mag Pharm Lukas Mayerhofer

Pharmacological expert Vienna

Lukas holds a graduate degree in pharmacy with extensive experience in natural products and drug formulation. He is an expert for the registration of new drug formulations and positioning of drugs, medical devices, food supplementary and cosmetics. He is a member of international advisory boards, was Head of the Global Health development program and is a consultant for development and distribution companies. He is the owner of a pharmacy and a pharmacy wholesale company. He worked more than ten years as advisor for the Global Health Group in Europe and China to position a new biocide.

Indraneil Mahapatra, MSc. MBA

Kingsley Capital, London

Neil holds a degree in Biological Sciences from the University of Oxford, where he was also President of the Oxford Union, and an MBA from the Harvard Business School. He began his career in investment banking at Morgan Stanley in London, before moving to J. Rothschild Capital Management, where he led private investments for Lord Rothschild’s family office and RIT Capital Partners plc. He is co-founder and managing partner of Kingsley Capital partners in London and is responsible for sourcing and managing investments across TMT and Life Sciences. He acts as a director of portfolio companies Oxford Cannabinoid Technologies, Atlas Tower Group, Intelligent Telecommunications Ltd, Spring Fibre Ltd, and Equinox International.